The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
<p dir="ltr">Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighte...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513542157238272 |
|---|---|
| author | Shahad Sabaawi Ibrahim (21842273) |
| author2 | Raghad Sabaawi Ibrahim (21842276) Batoul Arabi (21842279) Aranka Brockmueller (11064675) Mehdi Shakibaei (325455) Dietrich Büsselberg (11008857) |
| author2_role | author author author author author |
| author_facet | Shahad Sabaawi Ibrahim (21842273) Raghad Sabaawi Ibrahim (21842276) Batoul Arabi (21842279) Aranka Brockmueller (11064675) Mehdi Shakibaei (325455) Dietrich Büsselberg (11008857) |
| author_role | author |
| dc.creator.none.fl_str_mv | Shahad Sabaawi Ibrahim (21842273) Raghad Sabaawi Ibrahim (21842276) Batoul Arabi (21842279) Aranka Brockmueller (11064675) Mehdi Shakibaei (325455) Dietrich Büsselberg (11008857) |
| dc.date.none.fl_str_mv | 2024-05-27T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1007/s10555-024-10192-9 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/The_effect_of_GLP-1R_agonists_on_the_medical_triad_of_obesity_diabetes_and_cancer/29715761 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical biochemistry and metabolomics Nutrition and dietetics Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Ozempic Semaglutide Cancer Diabetes Obesity GLP1RA |
| dc.title.none.fl_str_mv | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer and Metastasis Reviews<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s10555-024-10192-9" target="_blank">https://dx.doi.org/10.1007/s10555-024-10192-9</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_0561ca7a78a8581ad07c86f71212436e |
| identifier_str_mv | 10.1007/s10555-024-10192-9 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29715761 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancerShahad Sabaawi Ibrahim (21842273)Raghad Sabaawi Ibrahim (21842276)Batoul Arabi (21842279)Aranka Brockmueller (11064675)Mehdi Shakibaei (325455)Dietrich Büsselberg (11008857)Biomedical and clinical sciencesMedical biochemistry and metabolomicsNutrition and dieteticsOncology and carcinogenesisPharmacology and pharmaceutical sciencesOzempicSemaglutideCancerDiabetesObesityGLP1RA<p dir="ltr">Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancer and Metastasis Reviews<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s10555-024-10192-9" target="_blank">https://dx.doi.org/10.1007/s10555-024-10192-9</a></p>2024-05-27T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s10555-024-10192-9https://figshare.com/articles/journal_contribution/The_effect_of_GLP-1R_agonists_on_the_medical_triad_of_obesity_diabetes_and_cancer/29715761CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/297157612024-05-27T09:00:00Z |
| spellingShingle | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer Shahad Sabaawi Ibrahim (21842273) Biomedical and clinical sciences Medical biochemistry and metabolomics Nutrition and dietetics Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Ozempic Semaglutide Cancer Diabetes Obesity GLP1RA |
| status_str | publishedVersion |
| title | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer |
| title_full | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer |
| title_fullStr | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer |
| title_full_unstemmed | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer |
| title_short | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer |
| title_sort | The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer |
| topic | Biomedical and clinical sciences Medical biochemistry and metabolomics Nutrition and dietetics Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Ozempic Semaglutide Cancer Diabetes Obesity GLP1RA |